Work

Formula-01: A phase Ⅱ study of disitamab vedotin (RC48) intravenous injection combined with BCG intravesical instillation in high-risk non-muscle invasive bladder cancer with HER2 high expression.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.tps894

Authors: Xingliang Tan, Yanjun Wang, Zhiming Wu, Wensu Wei, Qianghua Zhou, Chichen Zhang, Xinpei Deng, Runhao Zheng, Jiamin Zeng, Qiuhong Chen, Kai Yao

Institutions: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407699517

Cites:

Cited by:

Related to: 10